AU2011232347B2 - Compositions and methods for the treatment of degenerative diseases - Google Patents

Compositions and methods for the treatment of degenerative diseases Download PDF

Info

Publication number
AU2011232347B2
AU2011232347B2 AU2011232347A AU2011232347A AU2011232347B2 AU 2011232347 B2 AU2011232347 B2 AU 2011232347B2 AU 2011232347 A AU2011232347 A AU 2011232347A AU 2011232347 A AU2011232347 A AU 2011232347A AU 2011232347 B2 AU2011232347 B2 AU 2011232347B2
Authority
AU
Australia
Prior art keywords
alkyl
compound
aryl
formula
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011232347A
Other languages
English (en)
Other versions
AU2011232347A1 (en
Inventor
Craig Cano Beeson
Nathan R. Perron
Baerbel Rohrer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Publication of AU2011232347A1 publication Critical patent/AU2011232347A1/en
Priority to AU2015204390A priority Critical patent/AU2015204390A1/en
Application granted granted Critical
Publication of AU2011232347B2 publication Critical patent/AU2011232347B2/en
Assigned to MUSC FOUNDATION FOR RESEARCH DEVELOPMENT reassignment MUSC FOUNDATION FOR RESEARCH DEVELOPMENT Alteration of Name(s) of Applicant(s) under S113 Assignors: MEDICAL UNIVERSITY OF SOUTH CAROLINA
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011232347A 2010-03-24 2011-03-24 Compositions and methods for the treatment of degenerative diseases Ceased AU2011232347B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015204390A AU2015204390A1 (en) 2010-03-24 2015-07-17 Compositions and methods for the treatment of degenerative diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31718510P 2010-03-24 2010-03-24
US61/317,185 2010-03-24
PCT/US2011/029846 WO2011119869A1 (en) 2010-03-24 2011-03-24 Compositions and methods for the treatment of degenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015204390A Division AU2015204390A1 (en) 2010-03-24 2015-07-17 Compositions and methods for the treatment of degenerative diseases

Publications (2)

Publication Number Publication Date
AU2011232347A1 AU2011232347A1 (en) 2012-10-04
AU2011232347B2 true AU2011232347B2 (en) 2015-08-06

Family

ID=43927957

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011232347A Ceased AU2011232347B2 (en) 2010-03-24 2011-03-24 Compositions and methods for the treatment of degenerative diseases

Country Status (6)

Country Link
US (2) US20130137728A1 (enExample)
EP (1) EP2550260A1 (enExample)
JP (3) JP2013522376A (enExample)
AU (1) AU2011232347B2 (enExample)
CA (1) CA2794018C (enExample)
WO (1) WO2011119869A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
CN104703585A (zh) 2012-10-09 2015-06-10 宝洁公司 鉴定协同化妆品组合的方法
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9079853B2 (en) 2013-02-07 2015-07-14 Musc Foundation For Research Development Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
US20140275178A1 (en) * 2013-03-13 2014-09-18 Musc Foundation For Research Development Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
US8921401B2 (en) 2013-02-07 2014-12-30 Musc Foundation For Research Development Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
DK2956056T3 (da) 2013-03-14 2019-09-16 Univ Laval Elektroretinografisystem (erg) til vurdering af psykiatriske lidelser
CA2957785C (en) 2014-08-11 2023-01-03 Angion Biomedica Corporation Cytochrome p450 inhibitors and uses thereof
CA2970819A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp. Methods and agents for treating disease
CN104803946A (zh) * 2015-03-03 2015-07-29 佛山市赛维斯医药科技有限公司 含腈基噻唑和环戊二烯结构的ptp1b抑制剂及其用途
WO2016176420A1 (en) * 2015-04-30 2016-11-03 Musc Foundation For Research Development Oxindole compounds and pharmaceutical compositions thereof
HUE057041T2 (hu) 2015-07-06 2022-04-28 Alkermes Inc Hiszton deacetiláz hetero-halogén gátlói
WO2017007755A1 (en) 2015-07-06 2017-01-12 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
TWI666023B (zh) * 2016-09-26 2019-07-21 台灣粒線體應用技術股份有限公司 餘甘子萃取物用於製備保護視網膜中粒線體的醫藥組合物的用途
US10967019B2 (en) 2015-11-30 2021-04-06 Taiwan Mitochondrion Applied Technology Co., Ltd. Method for protecting mitochondria in retina cell
EP3426653B1 (en) * 2016-03-11 2021-12-15 AC Immune SA Bicyclic compounds for diagnosis and therapy
HRP20220223T1 (hr) 2017-01-11 2022-04-29 Alkermes, Inc. Biciklički inhibitori histon deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
MX2021012250A (es) 2019-04-11 2022-01-18 Angion Biomedica Corp Formas solidas de (e)-3-[2-(2-tienil)vinil]-1h-pirazol.
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
BR112022019113A2 (pt) 2020-03-26 2022-12-06 Diamentis Inc Sistemas e métodos para processar dados de sinal da retina e identificar condições
AU2022256476B2 (en) 2021-04-16 2025-06-05 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
KR20240138099A (ko) * 2022-01-26 2024-09-20 쑤저우 젠하우스 바이오 컴퍼니 리미티드 Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제
WO2023150878A1 (en) 2022-02-09 2023-08-17 Diamentis Inc. Systems and methods for retinal stimulation and/or collecting retinal signal data
EP4582423A1 (en) * 2022-10-13 2025-07-09 Hanmi Pharm. Co., Ltd. Novel tricyclic derivative compound and uses thereof
AR131380A1 (es) 2022-12-16 2025-03-12 Astrazeneca Ab Purinas 2,6,9-trisustituidas

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3852293A (en) * 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
US4260765A (en) * 1971-05-05 1981-04-07 Uniroyal, Inc. 2-(3-Pyridyl)-5-thiazolecarboxamides
US6303639B1 (en) * 1998-10-02 2001-10-16 Aventis Pharma Deutschland Gmbh Propanolamine derivatives substituted by heterocyclic radicals, processes for their preparation, pharmaceuticals comprising these compounds and their use
WO2002064545A1 (en) * 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2003101927A1 (en) * 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2008156869A2 (en) * 2007-06-20 2008-12-24 Sirtris Pharmaceuticals, Inc. Sirtuin modulating thiazolopyridine compounds
WO2009064388A2 (en) * 2007-11-09 2009-05-22 Liu Jun O Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57183768A (en) * 1981-05-06 1982-11-12 Kanto Ishi Pharma Co Ltd 4-methyl-5-(o-carboxyphenyl)carbamoylthiazole derivative and its preparation
US4788207A (en) * 1988-02-29 1988-11-29 Fmc Corporation Photoactivated miticidal and insecticidal ethynylthiazoles
EP1402900A1 (en) * 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
US7259175B2 (en) * 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
CA2599992A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Acridine and quinoline dervatives as sirtuin modulators
AR056317A1 (es) * 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
RU2007139634A (ru) * 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260765A (en) * 1971-05-05 1981-04-07 Uniroyal, Inc. 2-(3-Pyridyl)-5-thiazolecarboxamides
US3852293A (en) * 1972-06-21 1974-12-03 Uniroyal Inc 4-phenyl-2-(3-pyridyl)-thiazole carboxamides
US6303639B1 (en) * 1998-10-02 2001-10-16 Aventis Pharma Deutschland Gmbh Propanolamine derivatives substituted by heterocyclic radicals, processes for their preparation, pharmaceuticals comprising these compounds and their use
WO2002064545A1 (en) * 2001-02-13 2002-08-22 Aventis Pharma Deutschland Gmbh Acylated indanyl amines and their use as pharmaceuticals
WO2003101927A1 (en) * 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
WO2008156869A2 (en) * 2007-06-20 2008-12-24 Sirtris Pharmaceuticals, Inc. Sirtuin modulating thiazolopyridine compounds
WO2009064388A2 (en) * 2007-11-09 2009-05-22 Liu Jun O Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
CAPlus Accession No. 2010:514125 & CAS RN 1240328-31-7 *
CAS RN 1062380-56-6, STN Entry Date 17 October 2008 *
CAS RN 1090540-41-2, STN Entry Date 28 December 2008 *
CAS RN 1210928-46-3, STN Entry Date 17 March 2010 *
CAS RN 496022-60-7, STN Entry Date 28 February 2003 *
CAS RN 697229-44-0, STN Entry Date 22 June 2004 *
CAS RN 863312-03-2, STN Entry Date 16 September 2005 *
CAS RN 867294-85-7, STN Entry Date 11 November 2005 *
CAS RN 940270-59-7, STN Entry Date 29 June 2007 *
CAS RN 948643-50-3, STN Entry Date 28 September 2007 *
DIAS, N. et al., Biochemical Pharmacology, 2005, Vol. 70, pages 1-12 *
HOYE, A. T. et al, Accounts of Chemical Research, 2008, Vol. 41, No.1, pages 87-97 *
POPP, F. D., Journal of Heterocyclic Chemistry, 1982, Vol. 19, pages 589-592 *
SUZUKI, M. et al., Journal of the American Chemical Society, 1977, Vol. 99, pages 5083-5090 *
SZEWCZYK, A. et al, Pharmacological Reviews, 2002, Vol. 54, No. 1, pages 101-127 *
YAKIMOVICH, S. I. et al., Russian Journal of General Chemistry, 1994, Vol. 64, No. 9, pages 1339-1344 *
ZHANG, W.-T. et al, Journal of Medicinal Chemistry, 2009, Vol. 52, pages 718-725 *

Also Published As

Publication number Publication date
CA2794018C (en) 2016-05-10
AU2011232347A1 (en) 2012-10-04
JP2013522376A (ja) 2013-06-13
EP2550260A1 (en) 2013-01-30
JP2016188257A (ja) 2016-11-04
WO2011119869A1 (en) 2011-09-29
US20130137728A1 (en) 2013-05-30
JP2015232051A (ja) 2015-12-24
CA2794018A1 (en) 2011-09-29
US20160237074A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
CA2794018C (en) Compositions and methods for the treatment of degenerative diseases
US11931350B2 (en) Opioid receptor ligands and methods of using and making same
US5574044A (en) Muscarine antagonists
DE60023128T2 (de) Pyrazolcarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
JP5313125B2 (ja) スルホンアミド誘導体
US5691323A (en) Muscarine antagonists
DE69716810T2 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
KR101463572B1 (ko) Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물
CA2200468A1 (en) Muscarine antagonists
KR20060095865A (ko) 글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체
US20190008803A1 (en) Combinations of opioid receptor ligands and cytochrome p450 inhibitors
JP2004523475A (ja) タンパク質Ｊｕｎキナーゼのインヒビターとしての医薬的活性ベンズスルホンアミド誘導体
EP2300484B1 (en) Novel class of spiro piperidines for the treatment of neurodegenerative diseases
DE102004047272A1 (de) Inhibitoren der löslichen Adenylatzyklase
JP2004510772A (ja) タンパク質Ｊｕｎ−キナーゼのインヒビターとしての医薬的活性親水性スルホンアミド誘導体
DE602005001508T2 (de) 4-amino-5-cyanopyrimidinderivate
AU2015204390A1 (en) Compositions and methods for the treatment of degenerative diseases
EP1802572B1 (de) Indol derivative als inhibitoren der löslichen adenylatzyklase
RU2640047C2 (ru) Соль производного пирролидин-3-ил-уксусной кислоты и ее кристаллы
WO2007107384A2 (de) Inhibitoren der löslichen adenylatzyklase
CN121045075A (zh) 一类5,7-二氯-1,2,3,4-四氢异喹啉衍生物及其制备方法与应用
DE102005027274A1 (de) Inhibitoren der löslichen Adenylatzyklase
HK1191179B (en) Opioid receptor ligands and methods of using and making same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired